About: INSIGHT: a population scale COVID-19 testing strategy combining point-of-care diagnosis with centralised high-throughput sequencing

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: INSIGHT: a population scale COVID-19 testing strategy combining point-of-care diagnosis with centralised high-throughput sequencing Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	INSIGHT: a population scale COVID-19 testing strategy combining point-of-care diagnosis with centralised high-throughput sequencing
Creator	Brown, Tom Teichmann, Sarah Bassett, Andrew Suo, Chenqu Wang, Tengyao Wu, Qianxin
Source	BioRxiv
abstract	We present INSIGHT (Isothermal NASBA-Sequencing-based hIGH-througput Test): a two-stage COVID-19 testing strategy, using a barcoded isothermal NASBA reaction that combines point-of-care diagnosis with next generation sequencing, aiming to achieve population-scale COVID-19 testing. INSIGHT combines the advantages of near-patient with centralised testing. Stage 1 allows a quick decentralised readout for early isolation of pre-symptomatic or asymptomatic patients. The same reaction products can then be used in a highly multiplexed sequencing-based assay in Stage 2, confirming the near-patient testing results and facilitating centralised data collection. Based on experiments using commercially acquired human saliva with spiked-in viral RNA as input, the INSIGHT platform gives Stage 1 results within one to two hours, using either fluorescence detection or a lateral flow (dipstick) readout, whilst simultaneously incorporating sample-specific barcodes into the amplification product. INSIGHT Stage 2 can be performed by directly pooling and sequencing all post-amplification barcoded Stage 1 products from hundreds of thousands of samples with minimal sample preparation steps. The 95% limit of detection (LoD-95) for INSIGHT is estimated to be below 50 copies of viral RNA per 20 μl of reaction. Our two-stage testing strategy is suitable for further development into a rapid home-based and point-of-care assay, and is potentially scalable to the population level.
has issue date	2020-08-16(xsd:dateTime)
bibo:doi	10.1101/2020.06.01.127019
has license	biorxiv
sha1sum (hex)	af905665ba31f9c3f1336c707c253820d0d1b569
schema:url	https://doi.org/10.1101/2020.06.01.127019
resource representing a document's title	INSIGHT: a population scale COVID-19 testing strategy combining point-of-care diagnosis with centralised high-throughput sequencing
schema:publication	bioRxiv
resource representing a document's body	covid:af905665ba31f9c3f1336c707c253820d0d1b569#body_text
is schema:about of	named entity 'highly' named entity 'NASBA' named entity 'testing' named entity 'diagnosis' named entity 'performed' named entity 'early' named entity 'sequencing' named entity 'lateral' named entity 'combining' named entity 'amplification' named entity 'population' named entity 'barcodes' named entity 'confirming' named entity 'human' named entity 'Stage' named entity 'facilitating' named entity 'level' named entity 'Stage' named entity 'barcoded' named entity 'commercially' named entity 'testing' named entity 'Stage' named entity 'data collection' named entity 'sequencing' named entity 'asymptomatic' named entity 'saliva' named entity 'assay' named entity 'reverse transcriptase' named entity 'saliva' named entity 'fluorescence' named entity 'exact sequence' named entity 'primers' named entity 'saliva' named entity 'negative result' named entity 'single-stranded RNA' named entity 'lysate' named entity 'viral RNA' named entity 'lateral flow' named entity 'Public Health England' named entity 'NGS' named entity 'PCRD' named entity 'Qubit' named entity 'Isothermal' named entity 'NASBA' named entity 'primers' named entity 'viral RNA' named entity 'lysate' named entity 'RNA' named entity 'nucleic acid' named entity '95% confidence interval' named entity 'lateral flow' named entity 'saliva' named entity 'concatemer' named entity 'NASBA' named entity 'RNA' named entity 'primers' named entity 'RT-qPCR' named entity 'molecular beacon' named entity 'RT-qPCR' named entity 'fluorescence' named entity 'saliva' named entity 'denature' named entity 'nucleotides' named entity 'primers' named entity 'enzyme' named entity 'C-line' named entity 'fluorescence' named entity 'fluorophore' named entity 'NASBA' named entity 'lysate' named entity 'oligo' named entity 'NASBA' named entity 'NASBA' named entity 'NASBA' named entity 'NASBA' named entity 'titrated' named entity 'statistical model' named entity '2, 3' named entity 'amplicon'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software